CSU vaccine research advances, groundwork begins to develop coronavirus vaccine for the next pandemic
Researchers aim to create a vaccine candidate that would protect people from a spectrum of coronaviruses.
Tag: "Infectious Disease Research Center"
CSU alum leads state efforts for convalescent plasma consortium
Dr. John Eisenach was inspired by a mentor to create the Colorado COVID-19 Convalescent Plasma Project Consortium.
Research expenditures top $400 million, in historic first for CSU
Colorado State University’s spending on research activities reached a record $407 million for fiscal year 2020, a 2% increase over last year.
CSU researchers pivot, pursue, pioneer COVID-19 projects
Since the start of the coronavirus pandemic, Colorado State University has received more than $16 million in funding for COVID-19 research projects.
CSU secures $3.1 million from NIH to advance SolaVAX coronavirus vaccine research
Researchers at CSU have worked quickly and collaboratively to move this vaccine research forward.
An intertwined approach: CSU infectious disease experts make progress in national pandemic response
Sen. Cory Gardner was on campus to learn about CSU's work in testing, senior care facility surveillance and vaccine development.
CSU secures award from U.S. government for development of SolaVAX™ vaccine manufacturing process for SARS-CoV-2
A team of CSU researchers has entered into an agreement with the Biomedical Advanced Research and Development Authority to further develop a novel process that has the potential to inactivate the SARS-CoV-2 virus.
Using riboflavin, UV light in specialized device reduces SARS-CoV-2 pathogens in plasma, whole blood
The research team used existing technologies to treat nine plasma and three whole-blood products.
Company Week: Dr. Raymond Goodrich, Infectious Disease Research Center at CSU
Using a manufacturing platform developed to prevent the transmission of disease during blood transfusions, IDRC staffers are working with the faculty of several departments at CSU to test an internally developed vaccine candidate dubbed SolaVAX.
Researchers seek to repurpose an existing manufacturing platform to produce a COVID-19 vaccine
Over the last decade, there have been advances in manufacturing and in strategies to rapidly produce a vaccine.